Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review

References

• Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2606–2621. doi:10.1080/10428194.2019.1605071
   PubMed Web of Science ®Google Scholar
• Aldoss I, Stein AS. Advances in adult acute ­lymphoblastic leukemia therapy. Leuk Lymphoma. 2018;59(5):1033–1050. doi:10.1080/10428194.2017.1354372
   PubMed Web of Science ®Google Scholar
• Mustafa O, Abdalla K, AlAzmi AA, et al. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies. J Oncol Pharm Pract. 2019;25(8):1831–1838. doi:10.1177/1078155218817816
   PubMed Web of Science ®Google Scholar
• Crotta A, Zhang J, Keir C. Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia. Curr Med Res Opin. 2018;34(3):435–440. doi:10.1080/03007995.2017.1384373
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Jabbour E, Advani A. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:330–342. doi:10.1200/EDBK_280175
   PubMedGoogle Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866
   PubMed Web of Science ®Google Scholar
• Haslauer T, Greil R, Zaborsky N, et al. CAR T-Cell therapy in hematological malignancies. Int J Mol Sci. 2021;22 doi:10.3390/IJMS22168996
   Google Scholar
• Chen GM, Chen CH, Perazzelli J, et al. Characterization of leukemic resistance to CD19-Targeted CAR T-cell therapy through deep genomic sequencing. Cancer Immunol Res. 2023;11(1):13–19. doi:10.1158/2326-6066.CIR-22-0095/709811/AM/CHARACTERIZATION-OF-LEUKEMIC-RESISTANCE-TO-CD19
   PubMed Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–28. doi:10.1038/nm.4441
   PubMed Web of Science ®Google Scholar
• Xie B, Li Z, Zhou J, Wang W. Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. Cancers (Basel). 2022;14(13):3230. doi: 10.3390/cancers14133230.
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. 2nd Editio. Chichester (UK): John Wiley & Sons; 2019. doi:10.1002/9781119536604
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/BMJ.N71
   PubMed Web of Science ®Google Scholar
• Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–63. doi:10.1136/BMJEBM-2017-110853
   PubMedGoogle Scholar
• Shalabi H, Qin H, Su A, et al. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140(5):451–463. doi:10.1182/BLOOD.2022015795
   PubMed Web of Science ®Google Scholar
• Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419–1431. doi:10.1038/s41591-021-01436-0
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-Engineered universal CD19/CD22 Dual-Targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764–2772. doi:10.1158/1078-0432.CCR-20-3863
   PubMed Web of Science ®Google Scholar
• Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):53. doi:10.1186/S13045-020-00856-8/FIGURES/5
   PubMed Web of Science ®Google Scholar
• Schultz LM, Muffly LS, Spiegel JY, et al. Phase I trial using CD19/CD22 bispecific CAR T cells in pediatric and adult acute lymphoblastic leukemia (ALL). Blood. 2019;134(Supplement_1):744–744. doi:10.1182/blood-2019-129411
   Web of Science ®Google Scholar
• Tang X, Kang L, Qi W, et al. Tandem CAR T cells targeting CD19 and CD22 is a safe and highly efficacious treatment for relapse/refractory ALL patients. Blood. 2019;134(Supplement_1):1338–1338. doi:10.1182/blood-2019-127890
   Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–2138. doi:10.1172/JCI85309
   PubMed Web of Science ®Google Scholar
• Zhang C, He J, Liu L, et al. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. Blood Cancer J. 2022;12(6):96. doi:10.1038/s41408-022-00688-4
   PubMed Web of Science ®Google Scholar
• Ortiz-Maldonado V, Rives S, Español-Rego M, et al. Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. J Immunother Cancer. 2021;9(12):e003644. doi:10.1136/jitc-2021-003644
   PubMed Web of Science ®Google Scholar
• Lu W, Wei Y, Cao Y, et al. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Cancer Immunol Immunother. 2021;70(12):3501–3511. doi:10.1007/S00262-021-02941-4
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang XQ, Zhang RL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35(6):1563–1570. doi:10.1038/S41375-020-01056-6
   PubMed Web of Science ®Google Scholar
• Chen YH, Zhang X, Cheng YF, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020;22(12):755–761. doi:10.1016/j.jcyt.2020.08.002
   PubMed Web of Science ®Google Scholar
• Magnani CF, Gaipa G, Lussana F, et al. Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest. 2020;130(11):6021–6033. doi:10.1172/JCI138473
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang S, Fang H, et al. A phase I study of CAR-T bridging HSCT in patients with acute CD19+ relapse/refractory B-cell leukemia. Oncol Lett. 2020;20(4):20. doi:10.3892/OL.2020.11881
   PubMed Web of Science ®Google Scholar
• Wang J, Mou N, Yang Z, et al. Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia. Br J Haematol. 2020;191(2):212–222. doi:10.1111/BJH.16623
   PubMed Web of Science ®Google Scholar
• Roddie C, Dias J, O'Reilly MA, et al. Durable responses and low toxicity after fast off-Rate CD19 chimeric antigen Receptor-T therapy in adults with relapsed or refractory B-Cell acute lymphoblastic leukemia. J Clin Oncol. 2021;39(30):3352–3363. doi:10.1200/JCO.21.00917
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-Term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459. doi:10.1056/NEJMOA1709919
   PubMed Web of Science ®Google Scholar
• Gu R, Liu F, Zou D, et al. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1) doi:10.1186/s13045-020-00953-8
   Web of Science ®Google Scholar
• Shah BD, Bishop MR, Oluwole OO, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11–22. doi:10.1182/BLOOD.2020009098
   PubMed Web of Science ®Google Scholar
• Hu Y, Wu Z, Luo Y, et al. Potent anti-leukemia activities of chimeric antigen Receptor-Modified T cells against CD19 in chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res. 2017;23(13):3297–3306. doi:10.1158/1078-0432.CCR-16-1799
   PubMed Web of Science ®Google Scholar
• Yang J, He J, Zhang X, et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J. 2022;12(7) doi:10.1038/s41408-022-00694-6
   Web of Science ®Google Scholar
• Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127(20):2406–2410. doi:10.1182/BLOOD-2015-08-665547
   PubMed Web of Science ®Google Scholar
• Liu S, Deng B, Yin Z, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96(6):671–679. doi:10.1002/AJH.26160
   PubMed Web of Science ®Google Scholar
• Cordoba S, Onuoha S, Thomas S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27(10):1797–1805. doi:10.1038/s41591-021-01497-1
   PubMed Web of Science ®Google Scholar
• Wang J, Shen K, Mu W, et al. T cell defects: new insights into the primary resistance factor to CD19/CD22 cocktail CAR T-Cell immunotherapy in diffuse large B-Cell ­lymphoma. Front Immunol. 2022;13:1. doi:10.3389/FIMMU.2022.873789/FULL
   Web of Science ®Google Scholar
• Grover P, Veilleux O, Tian L, et al. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2022;6(5):1608–1618. doi:10.1182/BLOODADVANCES.2020003482
   PubMed Web of Science ®Google Scholar